Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
01167 JACOBIO-B
4.740
-0.210-4.24%
YOY
Do not show
Hide blank lines
(Q6)2022/06/30(FY)2021/12/31(Q6)2021/06/30(FY)2020/12/31
Assets
Current assets
Accounts receivable
-- -- -- -- -- 159.37M -- --
Advance deposits and other receivables
263.95% 38.69M 107.55% 32.68M 18.52% 10.63M 320.26% 15.74M
Cash and equivalents
-9.04% 1.47B -5.52% 1.54B 297.64% 1.61B 417.73% 1.63B
Derivative financial instruments-current assets
-- -- 480.36% 4.55M -- 2.64M -- 784K
Special items of current assets
-28.44% 20.29M -62.13% 64.92M -- 28.35M -- 171.41M
Total current assets
-15.87% 1.53B -9.67% 1.64B 337.53% 1.81B 470.71% 1.82B
Non-current assets
Property, plant and equipment
-2.85% 34.41M 12.57% 34.07M 43.83% 35.42M 13.63% 30.26M
Derivative financial instruments-non-current assets
-- 6.31M -- 2.86M -- -- -- --
Intangible assets
11.12% 1.21M 32.19% 1.55M -- 1.09M -- 1.17M
Special items of non-current assets
47.47% 33.83M 112.14% 43.64M 37.83% 22.94M 10.51% 20.57M
Total non-current assets
27.44% 75.76M 57.89% 82.11M 44.04% 59.45M 14.94% 52M
Total assets
-14.5% 1.6B -7.79% 1.72B 310.95% 1.87B 413.96% 1.87B
Liabilities
Current liabilities
Accounts payable
18.55% 57.19M 80.5% 51.05M 178.59% 48.24M 122.04% 28.28M
Other payables and accrued expenses
32.89% 21.82M -33.47% 24.87M 88.14% 16.42M 55.99% 37.38M
Derivative financial instrument-current liabilities
-- 588K -- -- -- -- -- --
Financial lease liabilities-current liabilities
-66.55% 3.38M -40.18% 4.92M 21.98% 10.09M -8.9% 8.22M
Total current liabilities
11% 82.97M 9.41% 80.83M 117.83% 74.75M 61.58% 73.88M
Net current assets
-17.03% 1.44B -10.48% 1.56B 357.37% 1.74B 539.39% 1.74B
Total assets less current liabilities
-15.56% 1.52B -8.5% 1.64B 326.68% 1.8B 464.68% 1.79B
Non-current liabilities
Financial lease liabilities-non-current liabilities
-79.25% 536K -6.07% 1.89M -75.54% 2.58M -81.39% 2.01M
Deferred income-non-current liabilities
-19.39% 1.82M -61.53% 2.02M -51.65% 2.25M -20.43% 5.26M
Total non-current liabilities
-51.35% 2.35M -46.19% 3.91M -99.72% 4.84M -99.08% 7.27M
Total liabilities
7.21% 85.32M 4.43% 84.75M -95.42% 79.59M -90.26% 81.15M
Total assets less total liabilities
-15.46% 1.52B -8.35% 1.64B 239.75% 1.79B 479.98% 1.79B
Total equity and non-current liabilities
-15.56% 1.52B -8.5% 1.64B 326.68% 1.8B 464.68% 1.79B
Equity
Share capital
0% 510K 1.59% 510K 862.26% 510K 1573.33% 502K
Other reserves
0.37% 4.11B 3.85% 4.1B 2397.97% 4.09B 2273.93% 3.95B
Retained profit
-12.72% -2.59B -13.93% -2.46B -58.83% -2.3B -239.82% -2.16B
Shareholders' Equity
-15.46% 1.52B -8.35% 1.64B 239.75% 1.79B 480.2% 1.79B
Total equity
-15.46% 1.52B -8.35% 1.64B 239.75% 1.79B 479.98% 1.79B
Total equity and total liabilities
-14.5% 1.6B -7.79% 1.72B 310.95% 1.87B 413.96% 1.87B
Currency Unit
CNYCNYCNYCNY
Accounting Standards
IASIASIASIAS
Audit Opinions
--Unqualified Opinion--Unqualified Opinion
Auditor
--PricewaterhouseCoopers--PricewaterhouseCoopers

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Jiakos Pharmaceutical Group Co., Ltd. is a Chinese investment holding company mainly engaged in clinical drug research and development. The company is mainly responsible for the independent discovery and development of innovative tumor therapy. The company's main drug development projects include JAB-3068 and allosteric SHP2 inhibitors in the clinical phase of JAB-3312. The company mainly does business in the domestic market.
CEO: Yinxiang Wang
Market: Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...